Brief: Verastem Oncology Announces First Patient Dosed With VS-7375, An Oral KRAS G12D Inhibitor, In US Phase 1/2A Trial In KRAS G12D Advanced Solid Tumors
24/06/2025 21:18
June 24 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY ANNOUNCES FIRST PATIENT DOSED WITH VERSUS-7375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, IN A U.S. PHASE 1/2A TRIAL IN KRAS G12D ADVANCED SOLID TUMORS Source text: ID:nBw8GY1WTa Further company coverage: VSTM.O ((Reuters.Briefs@thomsonreuters.com;))